Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Revenue: 2013-2025

Historic Revenue for Theravance Biopharma (TBPH) over the last 13 years, with Sep 2025 value amounting to $20.0 million.

  • Theravance Biopharma's Revenue rose 18.51% to $20.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.3 million, marking a year-over-year increase of 27.12%. This contributed to the annual value of $64.4 million for FY2024, which is 12.12% up from last year.
  • Latest data reveals that Theravance Biopharma reported Revenue of $20.0 million as of Q3 2025, which was down 23.69% from $26.2 million recorded in Q2 2025.
  • Theravance Biopharma's 5-year Revenue high stood at $26.2 million for Q2 2025, and its period low was $2.5 million during Q1 2022.
  • For the 3-year period, Theravance Biopharma's Revenue averaged around $16.7 million, with its median value being $15.7 million (2023).
  • Its Revenue has fluctuated over the past 5 years, first spiked by 850.47% in 2021, then slumped by 82.46% in 2022.
  • Over the past 5 years, Theravance Biopharma's Revenue (Quarterly) stood at $14.9 million in 2021, then declined by 1.99% to $14.6 million in 2022, then rose by 19.91% to $17.6 million in 2023, then rose by 6.77% to $18.8 million in 2024, then grew by 18.51% to $20.0 million in 2025.
  • Its Revenue stands at $20.0 million for Q3 2025, versus $26.2 million for Q2 2025 and $15.4 million for Q1 2025.